RF26 | PSAT150 Growth Outcomes From the Phase 2 and Phase 3 Studies of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency: Comparisons With Published Literature and an International Growth Study Database

BACKGROUND: Somatrogon is a long-acting recombinant human growth hormone (hGH) currently in development as a once-weekly injectable treatment for children with growth hormone deficiency (GHD). In a phase 2 (NCT01592500) and a phase 3 (NCT02968004) study, patients received either once-weekly somatrog...

Descripción completa

Detalles Bibliográficos
Autores principales: Cara, Jose, Carlsson, Martin, Rosenfeld, Ron G, Wajnrajch, Michael P, Wang, Ronnie, Zadik, Zvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625182/
http://dx.doi.org/10.1210/jendso/bvac150.1338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625182/
http://dx.doi.org/10.1210/jendso/bvac150.1338

Ejemplares similares